Literature DB >> 713415

[Saralasin-induced changes of blood pressure, renin and aldosterone in essential and renal hypertension (author's transl)].

J Beyer, G Liebau, B Steiner, K Hayduk.   

Abstract

In 34 patients saralasin was infused after variable degrees of sodium depletion in order to differentiate between essential and renin-induced hypertension. After sodium-depletion of short duration mean arterial pressure dropped more than 10 mm Hg in 9 of 25 patients with essential and in 7 of 9 patients with renin-induced hypertension. After long-lasting sodium depletion the fall of mean arterial pressure exceeded 10 mm Hg in 11 of 16 patients with essential and in 8 of 9 patients with renin-induced hypertension. Thus saralasin did not discriminate essential and renin-induced hypertension. Also, plasma renin concentration before and after saralasin did not allow to differentiate between the two forms of hypertension. The changes of renin during infusion of saralasin was negatively correlated to the change of blood pressure. Renal vein renin ratio in patients with renovascular hypertension was not modified by saralasin. Renin and aldosterone changed inversely during saralasin infusion.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 713415     DOI: 10.1007/bf01479836

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  13 in total

1.  [Hemodynamic changes after angiotensin II blockade by saralasin (author's transl)].

Authors:  G Liebau; J Beyer; D Larbig; K Schick; G Sekanina; K Hayduk
Journal:  Klin Wochenschr       Date:  1977-07-01

2.  Experience with renal vein renin ratios in the identification of a pressor kidney.

Authors:  J E Figueroa; D J Bennett; P T DeCamp; H M Batson
Journal:  South Med J       Date:  1975-10       Impact factor: 0.954

3.  Identification of angiotensinogenic hypertension in man using 1-sar-8-ala-angiotensin II (Saralasin, P-113).

Authors:  D H Streeten; J M Freiberg; G H Anderson; T G Dalakos
Journal:  Circ Res       Date:  1975-06       Impact factor: 17.367

4.  Renovascular hypertension: renin measurements to indicate hypersecretion and contralateral suppression, estimate renal plasma flow, and score for surgical curability.

Authors:  E D Vaughan; F R Bühler; J H Laragh; J E Sealey; L Baer; R H Bard
Journal:  Am J Med       Date:  1973-09       Impact factor: 4.965

5.  Improved assay methods for renin "concentration" and "activity" in human plasma. Methods using selective denaturation of renin substrate.

Authors:  S L Skinner
Journal:  Circ Res       Date:  1967-04       Impact factor: 17.367

6.  Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;.

Authors:  D H Streeten; G H Anderson; J M Freiberg; T G Dalakos
Journal:  N Engl J Med       Date:  1975-03-27       Impact factor: 91.245

7.  The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration.

Authors:  J J Brown; W C Brown; R Fraser; A F Lever; J J Morton; J I Robertson; E A Rosei; P M Trust
Journal:  Prog Biochem Pharmacol       Date:  1976

8.  Measurement of renin in both renal veins. Its use in diagnosis of renovascular hypertension.

Authors:  A M Michelakis; J H Foster; G W Liddle; R K Rhamy; O Kuchel; R D Gordon
Journal:  Arch Intern Med       Date:  1967-10

9.  Blockade and stimulation of renal, adrenal, and vascular angiotensin II receptors with 1-Sar, 8-Ala angiotensin II in normal man.

Authors:  N K Hollenberg; G H Williams; B Burger; I Ishikawa; D F Adams
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

10.  Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients.

Authors:  D B Case; J M Wallace; H J Keim; J E Sealey; J H Laragh
Journal:  Am J Med       Date:  1976-05-31       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.